High Tide Inc. announced plans to open its first Canna Cabana store in Peterborough, Ontario, pending regulatory approval, increasing its total Canadian locations to 233. This expansion builds on strong brand awareness and sales performance in Ontario, where Canna Cabana stores generate 2.4 times the provincial peer average revenue. The new store is strategically located in a busy plaza expected to attract consistent customer traffic. High Tide aims to continue organic growth funded by its cash flow while selectively pursuing acquisitions that fit its strategy and financial goals.
High Tide's plan to open its first Canna Cabana store in Peterborough, Ontario, is noted here with relevant market data for context. For readers following the Consumer Cyclical sector, 71 of 112 US stocks priced on Pluang rose today. As of Oct 01, 2026 13:51 WIB, VF Corp traded at USD 14.09 with a 1-day change of -2.83%, Ferrari NV at USD 392.85 down 2.29%, and Packaging Corporation of America at USD 228.13 down 2.21%.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linea...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
